4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Central Nervous System by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 15382 ongoing clinical trials involving Central Nervous System
Of the 15382 trials,5352 trials are in Phase II
Furthermore, 4134 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Central Nervous System by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Central Nervous System therapy area. The largest number of ongoing clinical trials for indications related to Central Nervous System therapy area is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in drug trials.

Yale University: The leading ongoing clinical trial sponsor for indications related to Central Nervous System therapy area

Yale University is the top clinical trial sponsor for indications related to the Central Nervous System therapy area.

Assiut University, Johns Hopkins University, Tehran University of Medical Sciences, and Cairo University are a few other notable clinical trials sponsors involved in Central Nervous System therapy area. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Central Nervous System

Ocrelizumab (Ocrevus), Eculizumab (Soliris), and Dimethyl fumarate (Tecfidera) are among the key marketed drugs marketed for the treatment of indications related to the Central Nervous System therapy area.

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) mechanism of action. It is formulated as concentrated solution and solution for intravenous route of administration. Ocrelizumab is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease, as a monotherapy for the management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity. Ocrelizumab was first approved in 2017 and is marketed globally including the US, the UK, France, Canada, and Australia by F. Hoffmann-La Roche Ltd and its subsidiaries.

Eculizumab (Soliris) is a humanized monoclonal antibody directed against terminal complement protein C5. It functions via Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Inhibitor mechanism of action. Soliris is formulated as injectable concentrated solution and injectable solution for intravenous route of administration. Soliris is indicated for the treatment of paroxysmal nocturnal hemoglobinuria in patients without a history of transfusion, atypical hemolytic uremic syndrome, for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy and for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Soliris (eculizumab) also indicated to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive, and for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Eculizumab was first approved in 2007 and is marketed globally including the US, the UK, France, Canada, and China by Alexion Pharmaceuticals Inc and its subsidiaries.